Canada · Delayed Price · Currency is CAD NervGen Pharma Statistics
Total Valuation
NervGen Pharma has a market cap or net worth of CAD 466.15 million. The enterprise value is 454.82 million.
| Market Cap | 466.15M |
| Enterprise Value | 454.82M |
Important Dates
The last earnings date was Wednesday, November 26, 2025.
| Earnings Date | Nov 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NervGen Pharma has 78.34 million shares outstanding. The number of shares has increased by 10.41% in one year.
| Current Share Class | 78.34M |
| Shares Outstanding | 78.34M |
| Shares Change (YoY) | +10.41% |
| Shares Change (QoQ) | +1.68% |
| Owned by Insiders (%) | 3.63% |
| Owned by Institutions (%) | 4.83% |
| Float | 65.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -158.46 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -17.79 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.79
| Current Ratio | 0.79 |
| Quick Ratio | 0.73 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -820.11% and return on invested capital (ROIC) is -493.00%.
| Return on Equity (ROE) | -820.11% |
| Return on Assets (ROA) | -88.77% |
| Return on Invested Capital (ROIC) | -493.00% |
| Return on Capital Employed (ROCE) | 857.89% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +95.12% in the last 52 weeks. The beta is 0.52, so NervGen Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | +95.12% |
| 50-Day Moving Average | 3.94 |
| 200-Day Moving Average | 3.55 |
| Relative Strength Index (RSI) | 69.40 |
| Average Volume (20 Days) | 133,735 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -25.24M |
| Pretax Income | -25.57M |
| Net Income | -25.57M |
| EBITDA | -25.20M |
| EBIT | -25.24M |
| Earnings Per Share (EPS) | -0.36 |
Balance Sheet
The company has 11.36 million in cash and 33,225 in debt, giving a net cash position of 11.33 million or 0.14 per share.
| Cash & Cash Equivalents | 11.36M |
| Total Debt | 33,225 |
| Net Cash | 11.33M |
| Net Cash Per Share | 0.14 |
| Equity (Book Value) | -2.94M |
| Book Value Per Share | -0.04 |
| Working Capital | -3.36M |
Cash Flow
| Operating Cash Flow | -16.76M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NervGen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.41% |
| Shareholder Yield | -10.41% |
| Earnings Yield | -5.49% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |